A paper published this month estimated that each year in the US about $28.2 billion, or half of the total spending on preclinical research, is used for preclinical studies that are not reproducible. “[T]he existence and propagation of one or more errors, flaws, inadequacies or omissions . . . that prevent replication of results” were […]